ADC Therapeutics SA NYSE:ADCT

ADC Therapeutics SA stock price today

$3.23
+1.20
+59.11%
Financial Health
0
1
2
3
4
5
6
7
8
9

ADC Therapeutics SA stock price monthly change

-46.86%
month

ADC Therapeutics SA stock price quarterly change

-46.86%
quarter

ADC Therapeutics SA stock price yearly change

+18.02%
year

ADC Therapeutics SA key metrics

Market Cap
189.51M
Enterprise value
N/A
P/E
-1.04
EV/Sales
-0.24
EV/EBITDA
0.28
Price/Sales
0.91
Price/Book
1.86
PEG ratio
-0.03
EPS
-2.75
Revenue
68.61M
EBITDA
-129.45M
Income
-226.56M
Revenue Q/Q
-4.94%
Revenue Y/Y
-62.38%
Profit margin
-96.18%
Oper. margin
-80.95%
Gross margin
97.33%
EBIT margin
-80.95%
EBITDA margin
-188.66%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

ADC Therapeutics SA stock price history

ADC Therapeutics SA stock forecast

ADC Therapeutics SA financial statements

ADC Therapeutics SA (NYSE:ADCT): Profit margin
Jun 2023 19.28M -47.11M -244.34%
Sep 2023 14.49M -47.80M -329.86%
Dec 2023 16.79M -85.03M -506.44%
Mar 2024 18.05M -46.60M -258.16%
ADC Therapeutics SA (NYSE:ADCT): Analyst Estimates
Mar 2024 18.05M -46.60M -258.16%
Sep 2025 12.19M -36.72M -301.24%
Oct 2025 23.44M -36.04M -153.79%
Dec 2025 24.52M -36.59M -149.23%
  • Analysts Price target

  • Financials & Ratios estimates

ADC Therapeutics SA (NYSE:ADCT): Debt to assets
Jun 2023 507302000 515.89M 101.69%
Sep 2023 466900000 521.08M 111.6%
Dec 2023 354782000 503.03M 141.79%
Mar 2024 307966000 502.41M 163.14%
ADC Therapeutics SA (NYSE:ADCT): Cash Flow
Jun 2023 -36.82M -1.01M 74.73M
Sep 2023 -34.01M -661K -2.30M
Dec 2023 -33.07M -527K 1.63M
Mar 2024 -44.09M -531K 356K

ADC Therapeutics SA alternative data

ADC Therapeutics SA (NYSE:ADCT): Employee count
Aug 2023 317
Sep 2023 317
Oct 2023 317
Nov 2023 317
Dec 2023 317
Jan 2024 317
Feb 2024 317
Mar 2024 273
Apr 2024 273
May 2024 273
Jun 2024 273
Jul 2024 273

ADC Therapeutics SA other data

23.23% -26.32%
of ADCT is owned by hedge funds
18.15M -20.67M
shares is hold by hedge funds

ADC Therapeutics SA (NYSE:ADCT): Insider trades (number of shares)
Period Buy Sel
Jan 2024 1332876 0
Feb 2024 484616 0
May 2024 14270446 29731
Jun 2024 0 32047
Jul 2024 800000 0
Dec 2024 200000 25352
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 50,000 $3.81 $190,500
Purchase
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 50,000 $2.28 $114,000
Purchase
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 50,000 $3.81 $190,500
Purchase
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 50,000 $2.28 $114,000
Sale
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 25,352 $2.07 $52,479
Purchase
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 400,000 $2.81 $1,124,000
Purchase
REDMILE GROUP, LLC 10 percent owner
Common Shares, par value CHF 0.08 per share 400,000 $2.81 $1,124,000
Sale
AZELBY ROBERT director
Common Shares 6,995 $2.89 $20,216
Sale
BIZZARI JEAN-PIERRE director
Common Shares 6,995 $2.89 $20,216
Sale
HUG PETER director
Common Shares 1,193 $2.89 $3,448
Patent
Application
Filling date: 18 Mar 2022 Issue date: 8 Sep 2022
Grant
Filling date: 8 Feb 2018 Issue date: 12 Jul 2022
Application
Filling date: 8 Feb 2019 Issue date: 9 Jun 2022
Grant
Filling date: 14 Jun 2018 Issue date: 3 May 2022
Application
Filling date: 22 May 2019 Issue date: 14 Apr 2022
Application
Filling date: 22 Sep 2021 Issue date: 31 Mar 2022
Application
Filling date: 30 Jul 2021 Issue date: 3 Feb 2022
Application
Filling date: 20 Jul 2021 Issue date: 20 Jan 2022
Application
Filling date: 20 Apr 2018 Issue date: 20 Jan 2022
Application
Filling date: 24 Sep 2021 Issue date: 13 Jan 2022
Thursday, 12 December 2024
seekingalpha.com
Wednesday, 11 December 2024
prnewswire.com
Monday, 9 December 2024
prnewswire.com
Friday, 6 December 2024
prnewswire.com
Monday, 2 December 2024
prnewswire.com
Saturday, 9 November 2024
seekingalpha.com
Friday, 8 November 2024
benzinga.com
Thursday, 7 November 2024
zacks.com
prnewswire.com
Tuesday, 5 November 2024
prnewswire.com
Monday, 4 November 2024
prnewswire.com
Friday, 1 November 2024
prnewswire.com
zacks.com
Thursday, 31 October 2024
prnewswire.com
Tuesday, 1 October 2024
globenewswire.com
Tuesday, 3 September 2024
globenewswire.com
globenewswire.com
Sunday, 11 August 2024
seekingalpha.com
Tuesday, 6 August 2024
zacks.com
globenewswire.com
Thursday, 1 August 2024
globenewswire.com
Tuesday, 30 July 2024
globenewswire.com
Thursday, 11 July 2024
investorplace.com
Monday, 8 July 2024
globenewswire.com
Thursday, 27 June 2024
globenewswire.com
Thursday, 13 June 2024
investorplace.com
Monday, 3 June 2024
globenewswire.com
Thursday, 30 May 2024
globenewswire.com
Wednesday, 15 May 2024
GlobeNewsWire
Thursday, 9 May 2024
GlobeNewsWire
  • What's the price of ADC Therapeutics SA stock today?

    One share of ADC Therapeutics SA stock can currently be purchased for approximately $3.23.

  • When is ADC Therapeutics SA's next earnings date?

    Unfortunately, ADC Therapeutics SA's (ADCT) next earnings date is currently unknown.

  • Does ADC Therapeutics SA pay dividends?

    No, ADC Therapeutics SA does not pay dividends.

  • How much money does ADC Therapeutics SA make?

    ADC Therapeutics SA has a market capitalization of 189.51M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 66.86% to 69.56M US dollars.

  • What is ADC Therapeutics SA's stock symbol?

    ADC Therapeutics SA is traded on the NYSE under the ticker symbol "ADCT".

  • What is ADC Therapeutics SA's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of ADC Therapeutics SA?

    Shares of ADC Therapeutics SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does ADC Therapeutics SA have?

    As Jul 2024, ADC Therapeutics SA employs 273 workers.

  • When ADC Therapeutics SA went public?

    ADC Therapeutics SA is publicly traded company for more then 5 years since IPO on 18 May 2020.

  • What is ADC Therapeutics SA's official website?

    The official website for ADC Therapeutics SA is adctherapeutics.com.

  • How can i contact ADC Therapeutics SA?

    ADC Therapeutics SA can be reached via phone at +41 21 653 02 00.

ADC Therapeutics SA company profile:

ADC Therapeutics SA

adctherapeutics.com
Exchange:

NYSE

Full time employees:

273

Industry:

Biotechnology

Sector:

Healthcare

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Biopole
Epalinges, 1066

CIK: 0001771910
ISIN: CH0499880968
CUSIP: H0036K147